These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14676048)

  • 1. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
    Hardmeier M; Wagenpfeil S; Freitag P; Fisher E; Rudick RA; Kooijmans-Coutinho M; Clanet M; Radue EW; Kappos L;
    Arch Neurol; 2003 Dec; 60(12):1736-9. PubMed ID: 14676048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
    J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.
    Hardmeier M; Wagenpfeil S; Freitag P; Fisher E; Rudick RA; Kooijmans M; Clanet M; Radue EW; Kappos L;
    Neurology; 2005 Jan; 64(2):236-40. PubMed ID: 15668419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
    Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study.
    Oreja-Guevara C; Rovaris M; Iannucci G; Valsasina P; Caputo D; Cavarretta R; Sormani MP; Ferrante P; Comi G; Filippi M
    Arch Neurol; 2005 Apr; 62(4):578-84. PubMed ID: 15824256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalamic damage and long-term progression of disability in multiple sclerosis.
    Rocca MA; Mesaros S; Pagani E; Sormani MP; Comi G; Filippi M
    Radiology; 2010 Nov; 257(2):463-9. PubMed ID: 20724544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.
    De Stefano N; Bartolozzi ML; Nacmias B; Zipoli V; Mortilla M; Guidi L; Siracusa G; Sorbi S; Federico A; Amato MP
    Arch Neurol; 2004 Apr; 61(4):536-40. PubMed ID: 15096402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A semiautomated measure of whole-brain atrophy in multiple sclerosis.
    Bermel RA; Sharma J; Tjoa CW; Puli SR; Bakshi R
    J Neurol Sci; 2003 Apr; 208(1-2):57-65. PubMed ID: 12639726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
    Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
    Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening.
    Janardhan V; Suri S; Bakshi R
    Radiology; 2007 Sep; 244(3):823-31. PubMed ID: 17690319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.
    Rudick RA; Lee JC; Simon J; Fisher E
    Ann Neurol; 2006 Aug; 60(2):236-42. PubMed ID: 16786526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis.
    Zivadinov R; Grop A; Sharma J; Bratina A; Tjoa CW; Dwyer M; Zorzon M
    J Neuroimaging; 2005 Jan; 15(1):27-36. PubMed ID: 15574571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.